Akari Therapeutics PLC (AKTX) — 10-K Filings
All 10-K filings from Akari Therapeutics PLC. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Akari Bets on Novel ADC Payload to Revolutionize Cancer Treatment
— Mar 30, 2026 Risk: high
Akari Therapeutics Plc (AKTX) is an oncology company focused on developing next-generation antibody-drug conjugates (ADCs) utilizing novel, proprietary payloads -
Akari Therapeutics Plc Files 2024 10-K
— Apr 15, 2025 Risk: medium
Akari Therapeutics Plc filed its 2024 10-K on April 15, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Celsus Thera
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX